Importantly, we showed that blockade of FXYD6 by its functional antibody generated by our laboratory significantly inhibited tumor growth in vivo. Thus, we present the first insight of FXYD6-mediated tumor progression and speculate that anti-FXYD6 therapy may be an effective strategy toward HCC treatment. The gene discussed is FXYD6; the disease is neoplasm.